Pipeline Overview

TRACON assets include two monoclonal antibodies and have been selected to possess advantageous safety profiles that will combine easily with existing therapies.

TRC093
TRC093 Preclinical Data Presentation at the 2009 AACR Meeting
TRC093 Phase 1 Data Presentation at the 2008 EORTC-NCI-AACR Meeting
A recombinant humanized IgG1 monoclonal antibody that inhibits angiogenesis, tumor cell growth, and cancer metastasis by binding cleaved collagen in the extracellular matrix of solid tumors. A Phase 1 trial of TRC093 in patients with advanced cancer was initiated on July 2007 and is nearly complete.

TRC105
TRC105 Preclinical Data Presentation at the 2009 AACR Meeting
TRC105 Phase 1 Data Presentation at the 2008 EORTC-NCI-AACR Meeting
TRC105 Phase 1 Data Presentation at the 2009 ASCO Meeting (poster)
TRC105 Phase 1 Data Presentation at the 2009 ASCO Meeting (slideshow)
A human chimeric monoclonal antibody that binds CD105 (or endoglin), a target that is essential for angiogenesis. This therapeutic antibody is expected to address multiple solid tumor types including breast, kidney, prostate, ovarian, and lung cancer. The antibody will also be developed for age-related macular degeneration (“AMD”), the most common cause of blindness. A Phase 1 trial of TRC105 for patients with advanced cancer is nearly complete and a large Phase 2 program is planned for 2009. In addition, study in patients with AMD is planned for late 2009.

TRC102
TRC102 Preclinical Data Presentation at the 2007 EORTC-NCI-AACR Meeting
TRC102 Phase 1 Data Presentation at the 2009 EORTC-NCI-AACR Meeting
TRC102 Preclinical Data Presentation at the 2009 AACR Meeting
TRC102 Phase 1 Data Presentation at the 2009 ASCO Meeting (poster)
TRC102 Phase 1 Data Presentation at the 2009 ASCO Meeting (slideshow)
TRC102 Phase 1 Data Presentation at the 2010 IASCL Workshop on Targeted Therapies in Lung Cancer

A small molecule inhibitor of base excision repair intended to reverse resistance to alkylator and antimetabolite chemotherapy, including agents used in the treatment of malignant melanoma, primary brain tumors, and lung cancer. The IND for TRC102 in combination with Temodar®, a chemotherapy drug manufactured and distributed by Schering-Plough, was approved by the United States Food and Drug Administration, or FDA, in 2006. Our research partner, Case Western University, began dosing TRC102 in combination with Temodar in a Phase 1 trial of cancer patients in February 2008. A second Phase 1 study of TRC102 combined with Alimta®, a chemotherapy drug manufactured by Eli Lilly, was initiated in cancer patients in June 2008